


a) CDTi priority areas

Ivermectin treatment 




b) Risks - SAEs in potential

LF and Loa loa >40% areas 



c). Benefits – ivermectin in

low-average LF areas 



d) STH recommended treatment

once yearly  twice yearly 
mass treatment unnecessary/undefined 




e) Risks – once yearly treatment

in LF and Loa loa >40% areas 




f) Benefits - large areas overlapping

with ivermectin treatment 




g) Bednet / ITN ownership

<35%  
>35%  



h) Risks - Low % of nets / ITNs

in potential LF and Loa loa >40% areas 



i) Benefits – higher % net/ITNs

in high prevalence LF area! 

